Archives
Nocodazole and Spiroplasma Entry into S2 Cells
2026-10-18
Wei et al. used Drosophila Schneider 2 cells to examine how Spiroplasma eriocheiris enters and damages host cells. The study linked cellular entry to clathrin-mediated endocytosis, macropinocytosis, actin filaments, and microtubules. Nocodazole-sensitive reductions in intracellular Spiroplasma copy number supported a role for microtubule-dependent host-cell processes, but did not by themselves establish direct transport along microtubules or distinguish entry from intracellular survival and replication.
Amlodipine: Product Identity and Mechanistic Scope
2026-10-17
The APExBIO product page identifies Amlodipine as a dihydropyridine calcium channel blocker and describes calcium-influx inhibition in vascular smooth muscle and cardiac muscle. Because no identity-matched study is available here, these statements support only a documented product and mechanism overview, not conclusions about assay performance, effect size, or clinical or experimental outcomes.
Cy7 Azide: Evidence-Limited Product Overview
2026-10-16
APExBIO describes Cy7 azide (non-sulfonated) as an azide-functionalized cyanine dye for fluorescent labeling of alkyne-modified biomolecules, including oligonucleotides. Its reported near-infrared optical properties support interpretation as a potential fluorescence readout, but the available material contains no identity-matched research paper establishing reaction performance, biological efficacy, or comparative advantages.
Sulfo-Cy7 NHS Ester: Scope and Evidence
2026-10-16
APExBIO’s product listing identifies Cy7 NHS ester as a sulfonated, water-soluble near-infrared fluorescent labeling reagent for amino-containing biomolecules. Its documented scope includes protein and peptide labeling and proposed in vitro or in vivo imaging, but no identity-matched research paper, independent performance study, comparator, or outcome statistics are available here.
Cy7 NHS Ester: Identity, Mechanism, and Evidence
2026-10-15
APExBIO describes Cy7 NHS ester (SKU A8109) as a sulfonated, water-soluble near-infrared dye intended for amino-group labeling of proteins and peptides. Its reported spectral properties support its use as a fluorescence reporter, but the available material is product information rather than identity-matched research evidence. It does not establish conjugation efficiency, labeling selectivity, biological compatibility, in vivo performance, or superiority to alternative dyes.
CY7-SE: What the Product Record Supports
2026-10-15
CY7-SE is identified by APExBIO as a sulfo-cyanine7 succinimidyl ester intended for fluorescent labeling of proteins, antibodies, and small molecules. The available product description supports a cautious account of its identity, stated optical properties, and conceptual use as a bioconjugation reagent, but it does not provide identity-matched study data establishing spectral performance, labeling efficiency, assay outcomes, or biological applicability.
Cy7 NHS Ester: Identity, Mechanism, and Evidence
2026-10-14
APExBIO describes Cy7 NHS ester, SKU A8109, as a sulfonated, water-soluble near-infrared labeling reagent for biomolecules containing accessible amino groups. Its reported optical properties support discussion of fluorescence measurement, but no identity-matched research paper is available here to establish labeling performance, biodistribution, imaging sensitivity, or biological safety.
Doxycycline and MMP-2-Responsive Cancer Research
2026-10-14
The cited 2024 study reports a peptide-based, MMP-2-responsive carrier for doxorubicin and indomethacin—not doxycycline. Its findings support a preclinical concept involving stimulus-responsive drug retention and immune effects, but they do not establish doxycycline efficacy, clinical benefit, or supplier equivalence.
Rhamnolipid LNPs as PEG Alternatives in mRNA Vaccines
2026-10-13
A 2026 Advanced Functional Materials study examined whether microbial rhamnolipids could replace PEG-lipids in mRNA lipid nanoparticles while adding intrinsic immune stimulation. The reported preclinical findings associate rhamnolipid-containing particles with stronger dendritic-cell uptake, lymph-node-directed expression, Th1-skewed immunity, and reduced PEG-associated findings under repeat dosing. However, the evidence remains model-dependent and does not establish clinical efficacy, long-term safety, or suitability of any commercial product.
SAR131675: Evidence and Limits of VEGFR-3 Inhibition
2026-10-13
SAR131675 is described by APExBIO as a selective ATP-competitive VEGFR-3 inhibitor with reported activity in biochemical, endothelial-cell, and mouse tumor models. The supplied evidence is preclinical and product-mediated rather than a cited primary research report; it does not establish clinical efficacy, safety, or relevance to nicotine-associated chronic kidney disease.
RPS6 in PDAC Signaling: Evidence and Limits
2026-10-12
A 2026 Oncogene study links LRRC8A–Caveolin-1 organization with KRAS/EGFR signaling, ribosome biogenesis, and pancreatic ductal adenocarcinoma growth. The findings are mechanistically suggestive but remain preclinical, and the supplied evidence does not establish RPS6 or the APExBIO antibody as a validated component of that study.
5-Methyl-CTP and OMV mRNA Vaccine Evidence
2026-10-12
The cited 2022 study provides preclinical evidence for bacteria-derived outer membrane vesicles as an mRNA antigen-delivery platform in mouse tumor models. It does not test 5-Methyl-CTP, establish that modified cytidine chemistry produced the reported effects, or demonstrate human efficacy and safety.
Sulfo-Cy7 NHS Ester: Identity and Evidence Scope
2026-10-11
Cy7 NHS ester (SKU A8109) is described by APExBIO as a sulfonated, water-soluble near-infrared fluorescent labeling reagent for biomolecular amino groups. The available evidence is limited to supplier documentation; no matched research paper was provided, so claims about labeling performance, imaging outcomes, biological distribution, or safety remain unverified here.
Necrosulfonamide: MLKL Inhibition and Evidence
2026-10-10
Necrosulfonamide (NSA) is a research MLKL inhibitor used to interrogate necroptotic cell death. Evidence supports its value as a mechanistic perturbation, but vendor-reported potency in HT-29 cells and findings from carbon-ion radiotherapy models should not be generalized across all cell types or disease settings.
Ginsenoside Rg1 and Treg-Mediated Neuroimmune Protection
2026-10-09
A 2025 mouse study identifies Ginsenoside Rg1 as a potential modulator of prolonged isoflurane-associated neuroimmune dysfunction, linking behavioral and synaptic changes to intestinal barrier disruption and regulatory T-cell loss. Its strongest contribution is a Treg-depletion experiment supporting, but not definitively proving, a gut–immune–brain mechanism that requires validation beyond this animal model.